All In Biotech

Drug Trial Radar · NCT00730964

A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.

A Post-marketing Surveillance Study of the Occurrence of Serious Adverse Reactions Among Patients Who Receive Optison in Routine Medical Practice

Last checked: Nov 20, 2026Latest source record: Jun 12, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

1,039

Actual

Start

May 2008

Primary completion

Oct 2009

Study completion Oct 2009

Sponsor

Lead sponsor
GE HealthcareIndustry
Sponsor type
Industry
First posted
Aug 8, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective surveillance trial will gather safety information for Optison when it is used in routine practice.

Conditions

  • Echocardiography

Interventions

  • Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP)Drug

    The recommended dose of Optison is 0.5mL injected into a peripheral vein. This may be repeated for further contrast enhancement as needed. The injection rate should not exceed 1mL per second. Follow the Optison injection with a flush of 0.9% sodium chloride injection, USP or 5% dextrose in water injection, United States Pharmacopeia (USP) . The maximum total dose should not exceed 5.0mL in any 10 minutes period. The maximum total dose should not exceed 8.7mL in any one patient study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Frequency of Serious Adverse Reactions (SAR)'s Among Subjects Who Receive Optison (Causally Related to the Product)During Contrast Enhanced Echocardiography in Routine Clinical Practice.Time frame: Within 24 hours post contrast administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GE Healthcare

    Princeton, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.